PSY18 - Comparing the Epidemiology of ADPKD in the US from 2010-2015 Using one Versus two Diagnosis Codes in Claims Data

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening genetic disease that progressively leads to end stage renal disease. Recent published literature in EU showed prevalence rates less than 5 in 10,000. However, there is currently very limited epidemiology data in the US. This study assessed the epidemiology of ADPKD using Truven MarketScan™ claims data from January 1, 2010 to December 31, 2015. The population was assessed in two cohorts with either one or two diagnosis of ADPKD required during the study period. The prevalence analysis required at least one (or two) encounter(s) with a diagnosis of ADPKD; the first referenced as Index date, with the incidence analysis requiring an additional step for continuous coverage for one year minus the index date with no encounters of ADPKD to ensure first diagnosis. Overall, annual prevalence rates varied from 14 to 18/100,000 and 10 to 14/100,000 in the one and two encounter groups. The average annual rates over the study period were 15/100,000 and 12/100,000 and would account for 47,850 and 38,280 patients in the one and two encounter groups respectively, assuming a US population of 319,000,000. It should be noted, however, that these prevalence rates account for the ADPKD population that is actively being treated. The incidence analysis was limited in reporting overall rates as less severe patients may appear new and be counted as an incident patient, particularly in slowly progressive diseases such as ADPKD. Therefore, the rates should primarily be used to compare trends over time, which demonstrated to be stable over the study period. This study is the first to assess the epidemiology of the ADPKD population using claims data. Results from both groups demonstrate that the prevalence of ADPKD in the US is low and the disease incidence was relatively stable from 2010 to 2015.